PR Newswire - 07 Aug 2024
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...
Targeted Oncology - 09 Jun 2024
The Targeted Pulse: Dostarlimab Achieves 100% Clinical Complete Response, FDA Acknowledges BLA for Zolbetuximab, and More ...